Literature DB >> 18024829

HIV and hepatitis B/C infections in patients donating blood for use as autologous serum eye drops.

Volker Weisbach1, Tina Dietrich, Friedrich E Kruse, Reinhold Eckstein, Claus Cursiefen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18024829      PMCID： PMC2095508          DOI： 10.1136/bjo.2007.117572

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN： 0007-1161            Impact factor:   4.638


× No keyword cloud information.
  8 in total

1.  HIV-1 infection transmitted by serum droplets into the eye: a case report.

Authors:  J Eberle; J Habermann; L G Gürtler
Journal:  AIDS       Date:  2000-01-28       Impact factor: 4.177

2.  [Autologous serum for otherwise therapy resistant corneal epithelial defects - Prospective report on the first 70 eyes].

Authors:  R Ferreira de Souza; F E Kruse; B Seitz
Journal:  Klin Monbl Augenheilkd       Date:  2001-11       Impact factor: 0.700

3.  [Screening for markers of transfusion-associated infections in autologous blood donation].

Authors:  R Zimmermann; N Schwella; V Weissbach; H G Heuft; R Eckstein
Journal:  Beitr Infusionsther Transfusionsmed       Date:  1994

4.  Discrepancies in the use of medications: their extent and predictors in an outpatient practice.

Authors:  S E Bedell; S Jabbour; R Goldberg; H Glaser; S Gobble; Y Young-Xu; T B Graboys; S Ravid
Journal:  Arch Intern Med       Date:  2000-07-24

5.  [Infection epidemiological data among blood donors in Germany 2003-2004. Report of the Robert Koch Institute in accordance with Article 22 of the Transfusion Act].

Authors:  R Offergeld; S Ritter; D Faensen; O Hamouda
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2005-11       Impact factor: 1.513

6.  Autologous serum eyedrops for dry eyes and epithelial defects: clinical and in vitro toxicity studies.

Authors:  A C Poon; G Geerling; J K Dart; G E Fraenkel; J T Daniels
Journal:  Br J Ophthalmol       Date:  2001-10       Impact factor: 4.638

Review 7.  Autologous serum eye drops for ocular surface disorders.

Authors:  G Geerling; S Maclennan; D Hartwig
Journal:  Br J Ophthalmol       Date:  2004-11       Impact factor: 4.638

8.  Comparison of autologous serum eye drops with conventional therapy in a randomised controlled crossover trial for ocular surface disease.

Authors:  B A Noble; R S K Loh; S MacLennan; K Pesudovs; A Reynolds; L R Bridges; J Burr; O Stewart; S Quereshi
Journal:  Br J Ophthalmol       Date:  2004-05       Impact factor: 4.638
  8 in total
  5 in total

1.  [On the use of autologous serum eyedrops in Germany : results of a survey among members of the Cornea Section of the German Ophthalmological Society (DOG)].

Authors:  K Kasper; L Godenschweger; D Hartwig; J D Unterlauft; B Seitz; G Geerling
Journal:  Ophthalmologe       Date:  2008-07       Impact factor: 1.059

2.  Human albumin eye drops as a therapeutic option for the management of keratoconjunctivitis sicca secondary to chronic graft-versus-host disease after stem-cell allografting.

Authors:  J T Seki; N Sakurai; S Moldenhauer; J Dam; E G Atenafu; P M Yip; T Mazzulli; T Henderson; J Pendergrast; C Cserti; J P Velazquez; R Simpson; G Felluga; H A Messner; J H Lipton
Journal:  Curr Oncol       Date:  2015-10       Impact factor: 3.677

Review 3.  [Ophthalmological complications in Sjögren's syndrome].

Authors:  C Jacobi; C Cursiefen
Journal:  Z Rheumatol       Date:  2010-02       Impact factor: 1.372

4.  [Manufacture of autologous serum eye drops for out-patient therapy : cooperation between ophthalmic clinic and transfusion medicine department].

Authors:  T Dietrich; V Weisbach; B Seitz; C Jacobi; F E Kruse; R Eckstein; C Cursiefen
Journal:  Ophthalmologe       Date:  2008-11       Impact factor: 1.059

Review 5.  [Autologous serum and alternative blood products for the treatment of ocular surface disorders].

Authors:  G Geerling; J D Unterlauft; K Kasper; S Schrader; A Opitz; D Hartwig
Journal:  Ophthalmologe       Date:  2008-07       Impact factor: 1.059
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.